摘要
The tumor microenvironment(TME)is composed of different cellular and non-cellular elements.Constant inter-actions between tumor cells and the TME are responsible for tumor initiation,tumor progression,and responses to therapies.Immune cells in the TME can be classified into two broad categories,namely adaptive and innate immunity.Targeting these immune cells has attracted substantial research and clinical interest.Current research focuses on identifying key molecular players and developing targeted therapies.These approaches may offer more efficient ways of treating different cancers.In this review,we explore the heterogeneity of the TME in non-small cell lung cancer,summarize progress made in targeting the TME in preclinical and clinical studies,discuss the potential predictive value of the TME in immunotherapy,and highlight the promising effects of bispecific antibodies in the era of immunotherapy.
基金
This study was conducted with support from the National Natural Science Foundation of China(No.82073147 to Q.J.)
supported by Foundation from Third Military Medical University(TMMU)(No.2018XLC1008).